Abstract:Rationale: Cell reprogramming technology is utilized to prevent cancer progression by transforming cells into terminally differentiated, non-proliferating states. Polypyrimidine tract binding protein 1 (PTBP1) is an RNA binding protein required for the growth of neurons and may directly transform multiple normal human cells into functioning neurons in vitro and in vivo when expressed at low levels. As a result, we identified it as a key to inhibiting cancer cell proliferation by boosting glioblastoma cell neural differentiation. Methods: Immunocytofluorescence (ICF) targeting TUJ1, MAP2, KI67, and EdU were utilized to evaluate glioblastoma cell reprogramming under PTBP1 knockdown or other conditions. PTBP1 and other target genes were detected using Western blotting and qRT-PCR. Activating protein phosphatase 2A (PP2A) and RhoA were detected using specific kits. CCK8 assays were employed to detect cell viability. Bioluminescence, immunohistofluorescence (IHF), and Kaplan-Meier survival analyses were utilized to demonstrate the in vivo reprogramming efficiency of PTBP1 knockdown in U87 murine glioblastoma model. In this study, RNA-seq technology was used to examine the intrinsic pathway. Results: The expression of TUJ1 and MAP2 neural markers, as well as the absence of KI67 and EdU proliferative markers in U251, U87, and KNS89 cells, indicated that glioblastoma cell reprogramming was successful. In vivo, U87 growth generated xenografts was substantially shrank due to PTBP1 knockdown induced neural differentiation, and these tumor-bearing mice had a prolonged survival time. Following RNA-seq, ten potential downstream genes were eliminated. Lentiviral interference and inhibitors blocking tests demonstrated that UNC5B receptor and its downstream signaling were essential in the neural differentiation process mediated by PTBP1 knockdown in glioblastoma cells. Conclusions: Our results indicate that PTBP1 knockdown promotes neural differentiation of glioblastoma cells via UNC5B receptor, consequently suppressing cancer cell proliferation in vitro and in vivo, providing a promising and feasible approach for glioblastoma treatment.

RBPJ maintains brain tumor–initiating cells through CDK9-mediated transcriptional elongation

RBBP6 maintains glioblastoma stem cells through CPSF3-dependent alternative polyadenylation

PDZ-Binding Kinase-Dependent Transcriptional Regulation of CCNB2 Promotes Tumorigenesis and Radio-Resistance in Glioblastoma.

Paired related homeobox 1 transactivates dopamine D2 receptor to maintain propagation and tumorigenicity of glioma-initiating cells

BRD4 Regulates Self-Renewal Ability and Tumorigenicity of Glioma-Initiating Cells by Enrichment in the Notch1 Promoter Region

RBM8A Promotes Glioblastoma Growth and Invasion Through the Notch/STAT3 Pathway

NCBP3/SNHG6 Inhibits GBX2 Transcription in a Histone Modification Manner to Facilitate the Malignant Biological Behaviour of Glioma Cells

CRB2 enhances malignancy of glioblastoma via activation of the NF-κB pathway

Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation

Data from MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor–Initiating Cells

Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase

Silencing BMI1 Eliminates Tumor Formation of Pediatric Glioma CD133+ Cells Not by Affecting Known Targets but by Down-Regulating a Novel Set of Core Genes

STEM-04. PD-1 INDEPENDENT OF PD-L1 LIGATION PROMOTES GLIOBLASTOMA GROWTH THROUGH THE NFkB PATHWAY

SATB2 Drives Glioblastoma Growth by Recruiting CBP to Promote FOXM1 Expression in Glioma Stem Cells

PTBP1 knockdown promotes neural differentiation of glioblastoma cells through UNC5B receptor

Transcriptional Regulation of Protein Synthesis by Mediator Kinase in MYC-driven Medulloblastoma

Transcriptional Regulation of Protein Synthesis by Mediator Kinase Represents a Therapeutic Vulnerability in MYC-driven Medulloblastoma

BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network

Methyltransferase Inhibition Enables Tgf β Driven Induction of CDKN2A and B in Cancer Cells

Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.

Histone lactylation-derived LINC01127 promotes the self-renewal of glioblastoma stem cells via the cis-regulating the MAP4K4 to activate JNK pathway